Cancer Biomarker Market Expansion 2024-2033: Growth Drivers and Dynamics

The cancer biomarker global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Cancer Biomarker Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The cancer biomarker market size has grown rapidly in recent years. It will grow from <b>$19.74 billion in 2023 to $22.77 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. </b> The growth in the historic period can be attributed to shift to personalized medicine, immunotherapy innovations, regulatory framework evolution, collaborative research efforts, focus on non-coding rnas.

The cancer biomarker market size is expected to see rapid growth in the next few years. It will grow to <b>$40.66 billion in 2028 at a compound annual growth rate (CAGR) of 15.6%. </b> The growth in the forecast period can be attributed to shift to patient-centric diagnostics, integration of biomarkers in clinical trials, emergence of multiplex biomarker panels, exploration of non-coding rnas, commercialization of biomarker tests. Major trends in the forecast period include advancements in genomics, precision medicine approaches, liquid biopsies, immunotherapy advancements, artificial intelligence (ai) integration.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Scope Of Cancer Biomarker Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Cancer Biomarker Market Overview

Market Drivers –
The rising incidence of cancer is driving the growth of the cancer biomarker market. The cancer incidence rate is the number of new cancers of a specific site/type that occur in a given population during a given year, represented as cancers per 100,000 people at risk. The increasing incidence of cancer is leading to the widespread use of cancer biomarkers because it helps in assessing disease risk, screening for occult primary tumors, identifying benign from malignant signs, or separating one form of malignancy from another. For instance, in January 2022, according to research published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. It is about 1,670 fatalities each day. Therefore, the rising incidence of cancer packaging is expected to propel the growth of the cancer biomarker market in the coming years.

Market Trends –
Technological advancement is a key trend gaining popularity in the cancer biomarker market. Major market players are developing advanced technologies, such as artificial intelligence (AI), deep learning (DL), and machine learning (ML), to sustain their position in the cancer biomarker market. These techniques are being used to tackle the problems associated with finding cancer biomarkers, where processing enormous volumes of molecular and imaging data are beyond the capabilities of conventional statistical studies and tools. For instance, in December 2021, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceuticals and diagnostics company introduced uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2), three new automated digital pathology algorithms that will be used as a biomarker for image analysis for breast cancer. This image analysis for breast cancer uses pathologist-trained deep learning algorithms to speed up the estimation of Ki-67, ER, and PR tumor cell nuclei positive.

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Get an inside scoop of the cancer biomarker market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Regional Insights –
North America was the largest region in the cancer biomaker market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –
Major companies operating in the cancer biomarker market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Table of Contents

1. Executive Summary
2. Cancer Biomarker Market Report Structure
3. Cancer Biomarker Market Trends And Strategies
4. Cancer Biomarker Market – Macro Economic Scenario
5. Global Cancer Biomarker Market Size and Growth
.
.
.
31. Global Cancer Biomarker Market Competitive Benchmarking
32. Global Cancer Biomarker Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Cancer Biomarker Market
34. Cancer Biomarker Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model